Claude

IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.

IntuitionLabs
SAS Life Sciences clinical programming, CDISC, and AI modernization consulting

SAS Life Sciences Consulting, Clinical Programming & AI Modernization

Validated SAS environments, CDISC SDTM/ADaM architecture, AI-assisted clinical programming, and selective SAS-to-Python/R modernization for pharma, biotech, and CROs preparing FDA, EMA, and PMDA submissions.

Our SAS Life Sciences Services

We help pharma sponsors and CROs extract more value from their SAS estate — through validated environment deployment, AI-augmented clinical programming, and selective modernization to Python and R where it improves outcomes without disrupting regulatory continuity.

AI Innovation
AI Integration
Connect Claude, GPT, and Gemini to your SAS pipeline for AI-assisted SDTM mapping, ADaM derivations, TLF drafting, and SAS-to-R/Python translation — all with full audit trails and human-in-the-loop review.
Explore AI integration
Compliance
GxP Validation
Validate SAS 9.4, LSAF, and SAS Viya environments to 21 CFR Part 11, EU Annex 11, and GAMP 5. Risk-based validation, controlled SDLC for SAS programs, and audit-ready documentation for FDA/EMA inspections.
View validation services
Implementation
CDISC & Submission Engineering
Architect CDISC SDTM/ADaM domains, Define-XML metadata, and end-to-end submission pipelines from EDC capture through eCTD Module 5 — aligned to FDA, EMA, and PMDA Study Data Standards.
Plan your submission

The Regulatory Standard for Clinical Submissions

SAS remains the de facto programming environment for clinical biostatistics because the FDA Study Data Standards Catalog formalizes SAS Transport (XPT) as the accepted dataset exchange format and because CDISC SDTM and ADaM standards were originally tooled in SAS. Virtually every NDA, BLA, and MAA reaching FDA, EMA, or PMDA is statistically analyzed in SAS — and that regulatory continuity is exactly why a careful, evidence-driven modernization strategy matters more than a rip-and-replace one.

SAS clinical submission package with SDTM, ADaM, and Define-XML metadata

From EDC to eCTD in One Validated Pipeline

A clinical SAS pipeline ingests raw data from Medidata Rave, Castor EDC, Veeva Vault CDMS, central labs, and ePRO/eCOA feeds; transforms it into SDTM tabulation domains; derives analysis-ready ADaM datasets; produces TLFs against the Statistical Analysis Plan; and packages everything with Define-XML metadata into eCTD Module 5.3.5.4. We build and validate the whole pipeline with ALCOA+ data integrity controls end-to-end.

Clinical data flow from EDC through SAS SDTM and ADaM into eCTD submission

AI Augmentation Without Regulatory Compromise

Modern LLMs — Anthropic Claude, OpenAI GPT, Google Gemini — are fluent in SAS syntax, macro language, PROC SQL, and CDISC conventions. We deploy them as productivity accelerators for your existing programmers with strict guardrails: every AI suggestion is logged, attributed to a model version, and subject to human review before reaching a validated program. The result is faster SDTM mapping and TLF drafting without weakening the controls FDA, EMA, and PMDA inspectors expect.

AI-assisted SAS programming workflow with human review and validated audit trails

What We Deliver Across the SAS Estate

Our SAS practice spans environment design, clinical programming architecture, AI augmentation, modernization strategy, integration with the broader pharma stack, and ongoing managed support for sponsor and CRO biostatistics teams.

Validated SAS Environments

Deploy SAS 9.4, SAS LSAF, or SAS Viya on AWS, Azure, GCP, or on-premise with full GAMP 5 validation, 21 CFR Part 11 controls, controlled program SDLC, and audit-ready documentation aligned to ISPE expectations.

Validation services

CDISC SDTM & ADaM Architecture

Design SDTM domain libraries, ADaM analysis dataset structures, controlled terminology, and Define-XML metadata. Build conformance testing using the SAS Clinical Standards Toolkit and Pinnacle 21 validators aligned to FDA conformance rules.

Plan submission

AI-Assisted Clinical Programming

Connect Claude, GPT, and Gemini to your SAS workflow for SDTM mapping suggestions, ADaM derivation drafting, TLF program scaffolding, and code review. All AI outputs logged and human-reviewed before merging into validated programs.

AI integration

EDC, eTMF & RWE Integration

Build validated data flows between SAS and Medidata Rave, Castor EDC, Veeva Vault CDMS, Suvoda IRT, Calyx ePRO, Snowflake, Databricks, and OHDSI OMOP CDM environments — with documented data transfer specifications and reconciliation.

Integration approach

SAS-to-R/Python Modernization

Selective migration of exploratory analytics, RWE, and post-hoc analyses to R (admiral, Tplyr, Pharmaverse) and Python (pandas, statsmodels) — with AI-assisted code translation and side-by-side validation against the SAS reference.

Discuss modernization

Managed Services & Inspection Support

Ongoing administration of validated SAS environments, periodic review of controlled SDLC, release validation across SAS and macro library updates, and audit support during FDA BIMO inspections and EMA GCP inspections.

Managed services

Why IntuitionLabs for SAS Life Sciences

We are not a body-shop SAS programming firm. IntuitionLabs combines deep CDISC and regulatory submission expertise with AI engineering and validated environment design — the rare combination that lets sponsors accelerate clinical programming without weakening the regulatory controls FDA and EMA inspectors expect.

AI-First, Not AI-Theater

We deploy AI as a programmer productivity multiplier with logged prompts, pinned model versions, and human-in-the-loop sign-off on every validated output.

Submission-Grade Discipline

21 CFR Part 11, CDISC SDTM/ADaM, Define-XML, GAMP 5, and ALCOA+ data integrity are core competencies — not adjacent ones.

Honest Modernization Advice

We will tell you when SAS is the right tool and when it is not — and we have the R/Python skills to support whichever direction your portfolio justifies.

SAS Integration Ecosystem

🔗

SAS + EDC (Medidata, Castor, Veeva CDMS)

Validated data flows from Medidata Rave, Castor EDC, Veeva Vault CDMS, and Oracle Clinical One into SAS with documented data transfer specifications, reconciliation reports, and full ALCOA+ chain of custody from EDC capture to SDTM tabulation.

✅

SAS + Pinnacle 21 & CDISC Validators

Automated SDTM and ADaM conformance checking against CDISC validation rules and the FDA Study Data Technical Conformance Guide, integrated into the SAS program lifecycle so issues surface during development rather than at submission.

🔁

SAS + R / Python (Pharmaverse)

Side-by-side execution of SAS and R-based pipelines using admiral, Tplyr, and metacore from the Pharmaverse — supporting cross-validation studies, exploratory analytics, and selective migration without disrupting the validated SAS core.

☁️

SAS + Snowflake / Databricks

Connect SAS to cloud data platforms for cross-trial RWE, integrated safety database queries, and commercial analytics — using SAS/ACCESS, Snowpark, and modern SQL pushdown for performance at petabyte scale.

🤖

SAS + AI Models (Claude, GPT, Gemini)

Connect external LLMs to your SAS workflow via REST orchestration for SDTM mapping suggestions, ADaM derivation drafting, TLF program scaffolding, SAS-to-R translation, and clinical data review — all with logged prompts and pinned model versions.

📦

SAS + eCTD Submission Build

End-to-end automation from SAS output through Define-XML generation, dataset packaging, and eCTD Module 5.3.5 assembly — integrated with eCTD publishing platforms used across the regulatory operations team for FDA, EMA, and PMDA filings.

Today's business insights

Profitable growth in the AI solutions industry

Our CEO discusses how AI is transforming the pharmaceutical industry and shares key strategies for leveraging AI in drug discovery and development.

More insights on unlock profitable growth in ai solutions
Profitable growth in the AI solutions industry

Getting Started With SAS

Every SAS engagement starts with mapping your current biostatistics estate — the studies in flight, the validated environment and macro libraries, the CDISC conformance level, the EDC and integration topology, and your near-term regulatory milestones across FDA, EMA, and PMDA. Whether you are deploying a new LSAF environment, modernizing SAS 9.4 to Viya, adding AI-assisted programming, or planning a hybrid SAS/R strategy, we tailor the approach to your portfolio and submission timeline.

Our team has supported clinical programming organizations from clinical-stage biotechs preparing first NDAs through global CROs running parallel portfolios across therapeutic areas. We bring the validation expertise and AI enablement capabilities that turn a SAS modernization into a measurable productivity gain rather than a tooling swap.

Engagement Models

  • Discovery Assessment — 2-week review of your SAS estate, CDISC maturity, environment topology, and modernization opportunities
  • Validated Environment Buildout — Deploy LSAF, SAS 9.4, or SAS Viya with full GAMP 5 validation and Part 11 controls (8-16 weeks)
  • AI Programming Pilot — Layer AI-assisted SDTM, ADaM, and TLF tooling onto your existing SAS workflow (6-12 weeks)
  • Managed Services — Ongoing administration, release validation, inspection support, and portfolio-level macro governance

Frequently Asked Questions

SAS — the analytics platform from SAS Institute — has been the dominant programming environment for clinical biostatistics, statistical analysis, and regulatory submissions for more than three decades. The reason is regulatory inertia: the FDA Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) accept clinical study datasets in the SAS Transport (XPT) file format as part of the Study Data Technical Conformance Guide, and CDISC standards (SDTM, ADaM, Define-XML) were originally tooled in SAS. Virtually every Phase 1-3 trial that reaches an NDA or BLA is statistically analyzed in SAS, and the regulatory artifacts — annotated CRFs, SDTM domains, ADaM analysis datasets, Tables/Listings/Figures (TLFs), and the Define-XML metadata — are produced by SAS programmers working under 21 CFR Part 11 controls. IntuitionLabs helps sponsors and CROs modernize their SAS estate — through validated environment deployment, AI-assisted programming, and selective migration to Python/R/Julia where it makes sense — without disrupting the regulatory continuity that the FDA, EMA, and PMDA expect.
The SAS portfolio relevant to life sciences spans several products. SAS Life Science Analytics Framework (LSAF) is the validated, regulatory-grade environment built specifically for clinical programming with version control, study-level access controls, and audit trails aligned to 21 CFR Part 11. SAS Clinical Standards Toolkit automates SDTM and ADaM compliance checking against CDISC validation rules. SAS Viya is the modern cloud-native analytics platform with REST APIs, Python/R integration, and CAS in-memory processing. SAS Health targets real-world evidence and population analytics. SAS 9.4 remains in heavy production use for legacy submission-grade work. We help organizations rationalize across these — keeping submission-grade SAS 9.4 / LSAF environments stable for ongoing trials while modernizing exploratory and RWE analytics on Viya or open-source stacks.
The CDISC standards form the structural backbone of modern clinical submissions. Raw EDC data from systems like Medidata Rave, Castor EDC, or Veeva Vault CDMS is mapped into SDTM (Study Data Tabulation Model) domains — DM, AE, CM, EX, LB, VS, and so on — which represent the standardized tabulation of trial data. SDTM datasets are then derived into ADaM (Analysis Data Model) datasets — ADSL, ADAE, ADLB, ADTTE — which carry the analysis-ready records used to produce TLFs for the Statistical Analysis Plan. The Define-XML metadata document then describes the structure, derivations, and controlled terminology so reviewers at FDA, EMA, and PMDA can navigate the submission package. We build and validate this pipeline end-to-end and ensure conformance against the FDA Study Data Technical Conformance Guide and the PMDA electronic study data submission requirements.
Yes, but selectively. The submission-grade portion of a sponsor or CRO estate — SDTM derivations, ADaM datasets, and the TLF programs cited in the SAP and the Clinical Study Report — should generally stay in SAS for ongoing trials because the FDA, EMA, and PMDA reviewers have decades of familiarity with SAS-produced artifacts and the FDA Study Data Standards Catalog formalizes SAS Transport as an accepted exchange format. However, exploratory analytics, real-world evidence work, machine learning, and post-hoc analyses are increasingly migrating to Python (using pandas and statsmodels) and R (using the Tplyr and admiral packages from the Pharmaverse). The R Consortium R Submissions Working Group has demonstrated end-to-end R-based submissions to FDA. IntuitionLabs helps sponsors run a portfolio strategy — SAS for the regulated core, open source for the modern frontier — with AI-assisted translation tooling that preserves traceability.
A validated SAS environment for clinical programming typically combines SAS Life Science Analytics Framework (LSAF) or an equivalent controlled SAS 9.4 / Viya deployment on AWS, Azure, or on-premise infrastructure, with formal validation artifacts aligned to ISPE GAMP 5 Second Edition. SAS itself is generally classified as a GAMP Category 3 (non-configured) or Category 4 (configured) product depending on usage. The validation package includes user requirements, configuration specification, FMEA-based risk assessment, IQ/OQ/PQ protocols, requirements-to-test traceability, and a validation summary report. 21 CFR Part 11 controls cover electronic signatures on study programs, immutable audit trails on the controlled workspace, password and session policies, and the controlled lifecycle of program code and metadata. We deliver these packages turnkey and tailor the depth to the risk classification of the work being performed. See our full validation services.
SAS sits in the middle of a complex clinical data flow. Upstream, it ingests raw datasets from EDC systems — Medidata Rave, Castor EDC, Veeva Vault CDMS, Florence eBinder, and Oracle Clinical One — plus central lab data, ePRO/eCOA feeds, and IRT/RTSM systems like Suvoda and Calyx. Downstream, SAS outputs flow into the eCTD submission build (Module 5.3.5 Clinical Study Reports, Module 5.3.5.4 datasets), into pharmacovigilance signal detection in Oracle Argus or ArisGlobal LifeSphere, and into commercial analytics in Snowflake or Databricks for cross-trial RWE. We build validated data pipelines with full chain of custody from EDC capture through final TLF, including documented data transfer specifications and reconciliation reports per MHRA GxP data integrity ALCOA+ expectations.
AI augments SAS in three high-value areas. First, AI-assisted SAS programming: Anthropic Claude and OpenAI GPT are surprisingly fluent in SAS syntax, PROC SQL, and macro language — accelerating SDTM mapping, ADaM derivation logic, and TLF program drafting with human statistical programmer review. Second, AI-assisted code translation between SAS and R/Python for cross-validation studies and exploratory analytics, preserving variable-level traceability. Third, AI-assisted clinical data review and signal detection: surfacing potential data quality issues, protocol deviations, and adverse-event clusters before the formal SAS analysis runs. Every AI output is logged, attributed to a model version, and subject to human review before influencing a regulated decision. Explore our SAS AI integration services.
SAS uses a subscription licensing model whose pricing is not publicly disclosed but is generally considered premium relative to open-source alternatives. Cost drivers include the number of named users or compute cores, the modules licensed (Base SAS, SAS/STAT, SAS/GRAPH, SAS Macro, Clinical Standards Toolkit, LSAF, Viya), the deployment topology (on-premise, SAS-hosted, AWS/Azure/GCP customer-managed), and the validation and managed-services overhead. The strategic question for many sponsors and CROs in 2026 is no longer "should we use SAS" but "how much of our analytics estate should remain in SAS versus migrate to Python/R," where licensing economics interact with hiring (younger biostatisticians often prefer R), regulatory acceptance (FDA now accepts R-based submissions), and AI tooling. IntuitionLabs helps clients build a five-year SAS portfolio strategy that balances regulatory inertia against modernization opportunity.
SAS Viya is the modern, cloud-native, microservices-based SAS platform — it runs natively on Kubernetes across AWS, Azure, Google Cloud, and Red Hat OpenShift, exposes REST APIs for orchestration, supports Python and R as first-class languages alongside SAS, and uses the CAS (Cloud Analytic Services) in-memory engine for high-performance analytics. Most pharma sponsors maintain a hybrid: SAS 9.4 (often in LSAF) for submission-grade clinical programming with deep historical investment in macro libraries and validated programs, and SAS Viya for newer exploratory analytics, model deployment, and integration with modern data platforms like Snowflake and Databricks. The transition is gradual because revalidating a stable SAS 9.4 trial pipeline for Viya is rarely justified mid-program. We help organizations plan a Viya adoption roadmap that aligns with portfolio milestones, infrastructure refresh cycles, and the modernization of statistical computing environments.
Data integrity in a clinical SAS pipeline must satisfy MHRA GxP data integrity guidance and the FDA data integrity guidance — meaning records must be Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available (ALCOA+). In practice this requires controlled SAS workspaces (LSAF or equivalent) with documented program lifecycle (draft, peer-reviewed, validated, locked); immutable audit trails on the workspace covering who ran what program when, against which input data version, producing what output; controlled metadata describing every derivation; and documented data transfer specifications when raw data moves from EDC to the SAS environment. We build these controls into the validated environment from day one, including automated reconciliation that compares EDC source extracts against SAS-loaded copies to catch transfer drift.
FDA reviewers in CDER and CBER receive submitted datasets via the eCTD format, typically as SAS Transport (XPT) files in Module 5.3.5.4 with accompanying Define-XML. Reviewers then load datasets into their own SAS environments (or, increasingly, JMP Clinical, R, and proprietary review tools) to independently re-run key analyses and verify the sponsor's TLFs. EMA follows similar conventions through the Policy 0070 clinical data publication framework. PMDA mandates electronic study data submission for new drug applications. The implication for sponsors is that the SAS output must be reproducible by reviewers — a requirement that drives the controlled SAS environment, controlled program lifecycle, and Define-XML metadata that we deliver as standard practice.
Many sponsors and large CROs offshore the bulk of statistical programming to India, China, or Eastern Europe — including Cognizant, Wipro, TCS, Syneos Health, IQVIA, Parexel, and ICON onshore/offshore models. IntuitionLabs does not compete with high-volume body-shop programming. Instead, we focus on the high-leverage middle: validated environment design, AI-assisted programming tooling that multiplies the productivity of your existing SAS programmers, complex SDTM/ADaM architecture for first-in-class therapeutic areas, modernization strategy across SAS and open source, and integration between SAS and the broader pharma stack (EDC, eTMF, RWE platforms, AI agents). We complement rather than replace your existing programming capacity — whether internal, CRO-delivered, or offshored.
Beyond interventional trials, SAS is widely used for real-world evidence (RWE) and observational studies analyzing claims, EHR, and registry data. SAS Health targets population analytics, and SAS programming is the dominant tool for Sentinel Initiative work and CMS Medicare claims analyses. The FDA RWE framework and the EMA Big Data Steering Group have both formalized the use of RWE in regulatory decision-making. We help sponsors build SAS-based RWE pipelines that connect to OHDSI OMOP Common Data Model implementations, claims data warehouses on Snowflake, and AI-enriched cohort definition workflows — bridging traditional SAS RWE with modern cloud analytics.
Engagements fall into four common shapes. (1) Validated SAS environment buildout — typically 8-16 weeks to deploy LSAF or controlled Viya on AWS/Azure with full GAMP 5 validation, controlled SDLC, and Part 11 controls. (2) CDISC SDTM/ADaM architecture for a new program — defining the standard structure, derivation rules, and metadata for a first study, then templating it for the rest of the portfolio. (3) AI modernization — adding AI-assisted programming, code review, and translation tooling on top of an existing SAS estate, typically a 6-12 week initial pilot. (4) SAS-to-R/Python migration strategy — usually a 4-6 week assessment producing a portfolio map of what stays, what migrates, and in what sequence. We size engagements to your specific program risk and timeline pressure, and we typically work alongside your existing biostatistics and statistical programming leadership rather than replacing them. Book a discovery call to discuss your portfolio.
Ready to Modernize Your SAS Estate?
Ready to Modernize Your SAS Estate? image

Ready to Modernize Your SAS Estate?

Book a discovery session to explore how validated SAS environments — extended with AI-assisted clinical programming and selective R/Python modernization — can accelerate your next FDA, EMA, or PMDA submission.

Book a Meeting

© 2026 IntuitionLabs. All rights reserved.

Privacy PolicyTerms of ServiceBook Meeting